REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
30/05/2026
Voltar para busca
Dado oficial do USPTO
MEREO
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
43
Atualização mais recente
31/05/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42
Data de depósito
04/05/2016
Data de registro
30/05/2017
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
05/02/2024
Última transação
31/05/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
708
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
GB
Examinador
CROWLEY, SEAN MICHAEL
Unidade examinadora
M70
Titulares e representantes
Titulares
Mereo BioPharma Group Plc
Mereo BioPharma Group Limited
Representantes
Anessa Owen Kramer Honigman LLP
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical and biopharmaceutical preparations and drugs for the treatment of rare and specialist diseases and conditions; pharmaceutical and biopharmaceutical preparations and drugs for the treatment of orphan diseases; pharmaceutical and biopharmaceutical preparations and drugs for the treatment of inflammatory diseases; pharmaceutical and biopharmaceutical preparations and drugs for the treatment of respiratory disorders; pharmaceutical and biopharmaceutical preparations and drugs for the treatment of chronic obstructive pulmonary disease (COPD); pharmaceutical and biopharmaceutical preparations and drugs for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD); pharmaceutical and biopharmaceutical preparations and drugsbronchodilators and anti-asthma preparations; pharmaceutical and biopharmaceutical preparations and drugs for the treatment of osteogenesis imperfecta (OI) (brittle bone syndrome); pharmaceutical and biopharmaceutical preparations and drugs to improve bone density and treat bone weakness; pharmaceutical and biopharmaceutical preparations and drugs for the treatment of obesity; pharmaceutical and biopharmaceutical preparations and drugs for normalising testosterone levels; pharmaceutical and biopharmaceutical preparations and drugsaromatase inhibitors (AIs); pharmaceutical and biopharmaceutical preparations and drugs for treating hypogonadotrophic hypogonadism (HH); antibiotics
Classe 42
Scientific research and design relating thereto; industrial analysis and research services in the field of medicine and disease; medical and pharmaceutical research services; scientific research for medical purposes; researchinspectiontestingdevelopment and evaluation of the pharmaceutical products of others in the field of medicine and disease; researchinspectiontestingdevelopment and evaluation of pharmaceutical and veterinary preparationsproducts and drugs; conducting clinical trials for others; informationadvisory and consultancy services relating to all the aforesaid services
Publicações
Histórico de despachos e eventos da marca no USPTO.
43 publicações encontradas
RNWL
INTERNATIONAL REGISTRATION RENEWED
16/04/2026
NREP
NEW REPRESENTATIVE AT IB RECEIVED
19/02/2026
LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
11/08/2025
RHRD
RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
06/12/2024
INNP
PARTIAL INVALIDATION PROCESSED BY THE IB
29/11/2024
INPS
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
22/10/2024
INPC
INVALIDATION PROCESSED
22/10/2024
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
06/10/2024
NA75
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
05/02/2024
C75P
REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK.
05/02/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
29/01/2024
ES75
TEAS SECTION 71 & 15 RECEIVED
30/05/2023
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
30/05/2022
LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
28/01/2019
RHRD
RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
17/01/2019
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
28/10/2017
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
13/10/2017
FICS
FINAL DISPOSITION NOTICE SENT TO IB
08/09/2017
FIMP
FINAL DISPOSITION PROCESSED
08/09/2017
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
30/08/2017
R.PR
REGISTERED-PRINCIPAL REGISTER
30/05/2017
PUBO
PUBLISHED FOR OPPOSITION
14/03/2017
GPNX
NOTIFICATION PROCESSED BY IB
10/03/2017
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/03/2017
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
22/02/2017
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
22/02/2017
NPUB
NOTICE OF PUBLICATION
22/02/2017
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
09/02/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
20/01/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
19/01/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
19/01/2017
ALIE
ASSIGNED TO LIE
18/01/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
19/12/2016
RFNT
REFUSAL PROCESSED BY IB
16/09/2016
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
30/08/2016
RFRR
REFUSAL PROCESSED BY MPU
30/08/2016
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
30/08/2016
CNRT
NON-FINAL ACTION WRITTEN
29/08/2016
DOCK
ASSIGNED TO EXAMINER
20/08/2016
MAFR
APPLICATION FILING RECEIPT MAILED
26/07/2016
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
22/07/2016
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
21/07/2016
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace MEREO ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.